Search

Search Constraints

You searched for: Date 2018 Author/Creator Reuben, Alexandre

Search Results

1. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. (4th May 2018)

2. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. (December 2018)

3. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. (November 2018)

4. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Issue 2 (February 2018)

5. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. (December 2018)